“To address hepatitis C to date there are basically two combination therapies, very well tolerated, which can allow rapid recovery. For this reason the main problem shifts more to identifying the patients who remain to be treated. The idea, with a view to eliminating the virus, is to find these patients and send them to treatment as quickly as possible because with a couple of months of treatment we close the game “. Thus Giuliano Rizzardini, director of the Infectious Diseases Department of the Sacco hospital in Milan, who spoke during the XX National Simit Congress. “The Ministry of Health has given funds to implement these strategies which have, however, remained somewhat blocked by Covid – continues Rizzardini – The hope is that the pressure of the pandemic will decrease and we will be able to start again to identify the so-called submerged”. hepatitis C the short therapies available are showing several advantages: “The short therapies have few side effects and allow you to be sure that a tight adherence is maintained – explains Rizzardini -. A brief therapy is more likely to be completed, in fact we have obtained positive results in 99% of cases “.